Algorae Pharmaceuticals Ltd (ASX:1AI): Commercial Expansion, AI Drug Discovery and FY26 Developments

Aditi Sarkar

06 October 2026 03:48 PM AEDT

Algorae Pharmaceuticals Ltd (ASX:1AI): Commercial Expansion, AI Drug Discovery and FY26 Developments

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Algorae Pharmaceuticals Ltd (ASX:1AI) operates through AlgoraeRx, its pharmaceutical commercialisation division, and AlgoraeOS, its AI-enabled drug discovery platform.
During 2026, the company expanded its pharmaceutical portfolio through agreements covering oncology, cardiovascular, metabolic and other medicines for Australia and New Zealand.
AlgoraeOS v2 generated more than 9 million in-silico synergy predictions across 18 anchor drugs, with further candidate prioritisation underway.
At the time of writing this article, Algorae Pharmaceuticals Ltd (ASX:1AI) was trading at AUD 0.009, up 5.88% during today’s trading session.

At the time of writing this article, Algorae Pharmaceuticals Ltd (ASX:1AI) was trading at AUD 0.009, up 5.88% during today’s trading session. Algorae is an Australian pharmaceutical company combining commercial medicine Supply with research and development. Its operating model includes AlgoraeRx, which sources, registers and supplies pharmaceutical products across Australia and New Zealand, and AlgoraeOS, an AI-enabled platform used to identify drug-combination candidates. During FY26, the company expanded both areas through pharmaceutical supply agreements, regulatory activity and further development of its AI platform.

Company Business

Algorae operates a dual Business model spanning pharmaceutical commercialisation and drug discovery. AlgoraeRx focuses on sourcing generic and specialty medicines from international manufacturers, undertaking regulatory processes and supplying products into Australian and New Zealand markets. The division operates through a source-register-supply model, with product commercialisation dependent on applicable regulatory approvals.

AlgoraeOS is the company’s proprietary AI-powered drug discovery platform. The platform has been developed with research partners and is designed to analyse biological, chemical and clinical data to identify potential drug combinations. The company’s development portfolio also includes programs such as AI-116, AI-168 and NTCELL.

Recent Development

During 2026, Algorae continued expanding its commercial pharmaceutical portfolio. In February, the company finalised a licence and supply agreement covering two generic medicines for cardiovascular and metabolic disorders in Australia and New Zealand. Under the agreement, the Manufacturing partner is responsible for product development and manufacture, while Algorae is responsible for regulatory sponsorship and commercialisation through AlgoraeRx.

In April, Algorae entered an exclusive commercial and licensing agreement covering 10 injectable, oral and specialty pharmaceutical products intended for Australia and New Zealand. Commercialisation of those products remains subject to applicable regulatory approvals.

The company also continued development of AlgoraeOS. In May 2026, Algorae reported completion of the prediction-generation phase of a multi-anchor drug-combination program using AlgoraeOS v2. The platform generated more than 9 million potential drug-drug-cell-line combinations across 18 anchor drugs. Preliminary filtering identified more than 478,000 synergy predictions and over 6,000 combinations meeting additional biological generalisability criteria.

Financial Performance and Sector Context

Algorae’s FY26 period reflected increased expenditure associated with commercial pharmaceutical activities and research and development. The company reported a net loss after tax of approximately $2.7 million for FY26, compared with approximately $0.8 million in FY25.

At 30 June 2026, the company reported cash of approximately $3.94 million, comprising bank cash and call deposits. FY26 operating cash outflows were approximately $2.60 million. During the June quarter, operating cash outflow was approximately $1.60 million, including Research and Development expenditure and product manufacturing and operating costs.

Earlier in 2026, Algorae raised approximately $3.99 million before costs through option exercises and a share placement. Following that Capital raising, the company reported a pro-forma cash balance of approximately $5.56 million and access to a $3 million receivables-based Debt facility.

The pharmaceutical sector requires companies to manage regulatory approval processes, product supply, inventory requirements and clinical or preclinical development. These factors can result in expenditure occurring before material commercial Revenue is recognised.

Risks to Consider

Algorae remains exposed to Regulatory Risk because several products within its commercial portfolio require approvals before launch. Delays in registration, product manufacturing or supply could affect commercialisation timelines.

The company is also exposed to research and development risk through AlgoraeOS and its therapeutic programs. AI-generated predictions require laboratory validation and further development before they can support potential commercial applications. Funding requirements, operating cash outflows and execution across multiple commercial agreements are additional considerations.

What to Watch Next

Future developments include progress in registering and commercialising products covered by AlgoraeRx supply and licensing agreements. Regulatory submissions and subsequent product launches will determine how the commercial portfolio develops.

For AlgoraeOS, investors may monitor the prioritisation and validation of candidates generated through the multi-anchor program. The company has indicated that shortlisted combinations may be used in further independent validation work.

Quarterly reports will also provide further information on cash expenditure, product-related payments, research activity and any movement toward commercial revenue.

Key Insights

Algorae Pharmaceuticals spent FY26 expanding from an R&D-focused biotechnology company into a broader pharmaceutical business combining commercial supply activities with AI-assisted drug discovery.

AlgoraeRx now includes multiple pharmaceutical agreements across different therapeutic areas, while AlgoraeOS v2 has generated a large dataset of drug-combination predictions for further assessment. The company also raised additional capital during 2026 to support its commercial and research activities. Key factors to monitor include regulatory approvals, product commercialisation, cash expenditure and further validation of AlgoraeOS-generated candidates.

FAQs

Q:What does Algorae Pharmaceuticals Ltd do?

A:Algorae operates pharmaceutical commercialisation activities through AlgoraeRx and AI-enabled drug discovery activities through AlgoraeOS.

Q:What is AlgoraeRx?

A:AlgoraeRx is the company’s commercial pharmaceutical division, focused on sourcing, registering and supplying generic and specialty medicines in Australia and New Zealand.

Q:What is AlgoraeOS?

A:AlgoraeOS is Algorae’s proprietary AI-powered drug discovery platform used to generate and prioritise potential drug-combination candidates.

Q:How much cash did Algorae report at 30 June 2026?

A:The company reported approximately $3.94 million in cash at the end of FY26.

Q:What are the key developments to monitor next?

A:Key areas include pharmaceutical regulatory approvals, product commercialisation, AlgoraeOS validation programs, research expenditure and future cash-flow updates.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.